Change - Announcement of Appointment::Change - Announcement of Appointment

Issuer & Securities

Issuer/ Manager
THOMSON MEDICAL GROUP LIMITED
Securities
THOMSON MED S$120M5.5%N280531 - SGXF52537366 - V2AB
THOMSON MED S$175M4.05%N250128 - SGXF89249654 - RMEB
THOMSON MEDICAL GROUP LIMITED - SG1M49904634 - A50
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
11-Oct-2023 18:46:43
Status
New
Announcement Sub Title
Change - Announcement of Appointment
Announcement Reference
SG231011OTHR93FM
Submitted By (Co./ Ind. Name)
Dr Heng Jun Li Melvin
Designation
Executive Director and Group CEO
Description (Please provide a detailed description of the event in the box below)
Appointment of Lee Suen Ming as Chief Executive Officer, Thomson Medical Singapore, with effect from 1 November 2023

Additional Details

Date Of Appointment
01/11/2023
Name Of Person
Lee Suen Ming
Age
54
Country Of Principal Residence
Singapore
The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process)
The Nominating and Remuneration Committee (NRC) of the Company, having reviewed Mr Lee's qualifications and work experience, has recommended to the Board that Mr Lee be appointed as Chief Executive Officer, Thomson Medical Singapore, with effect from 1 November 2023. The Board has reviewed and approved the appointment of Mr Lee as Chief Executive Officer, Thomson Medical Singapore.
Whether appointment is executive, and if so, the area of responsibility
Executive and to oversee the Singapore operations of Thomson Medical Group including Thomson Medical Centre and specialist medical clinics of Thomson Medical Pte Ltd
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Chief Executive Officer, Thomson Medical Singapore
Professional qualifications
- Joint Advanced Management Program at University of California, Berkeley and Nanyang Technological University

- MBA at Universitas 21 (which is a consortium of 29 research-intensive international universities including The University of Melbourne and National University of Singapore)

- Imperial College London: Bachelor of Electrical & Electronic Engineering (First Class Direct Honors)
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
No
Conflict of interests (including any competing business)
No
Working experience and occupation(s) during the past 10 years
Jun 2023 to Sep 2023
Advisor for EQT AB, Singapore (Healthcare Consultancy)

May 2022 to May 2023
Fakeeh Care Group
- CEO, Dr Soliman Fakeeh Hospital
- CEO, Ambulatory Medical Services

Feb 2017 to May 2022
IHH Healthcare
- CEO, Gleneagles Hospital (Feb 2017 to Dec 2018)
- Vice President, Singapore Operations Division Group (Jan 2019 to Jul 2019)
- CEO, Parkway East Hospital (Aug 2019 to Jul 2021)
- Vice President, Operational Development (Aug 2021 to May 2022)

Oct 2014 to Dec 2016
CEO, Mount Alvernia Hospital

May 2011 to Oct 2014
Singapore Power Ltd
- Vice President, Strategic Investments
- Managing Director, Finance

Feb 2002 to May 2011
National Healthcare Group
- Assistant Director, The Heart Institute
- Deputy Director, Bed Management Unit
- Director of Operations, Tan Tock Seng Hospital

Aug 1993 to Feb 2002
DBS Bank
- Assistant Treasurer (1994 to 1996)
- General Manager, DBS Los Angeles (1996 to 2000)
- Advisory Banker, DBS Bank (2000 to 2002)
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
No
Other Principal Commitments* Including Directorships#
*"Principal Commitments" has the same meaning as defined in the Code
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
None
Present
None
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Disclosure applicable to the appointment of Director only.
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
NA, not an appointment of Director
Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable)
NA